Patents Assigned to Rappta Therapeutics Oy
  • SUBSTITUTED CYCLIC MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME
    Publication number: 20240174611
    Abstract: The present disclosure relates in part to chemical modulators of protein phosphatase 2A (PP2A). The compounds of the present disclosure are useful in treating, preventing, and/or ameliorating cancer, diabetes, autoimmune disease, solid organ transplant rejection, graft vs host disease, chronic obstructive pulmonary disease (COPD), non-alcoholic fatty liver disease, abdominal aortic aneurysm, chronic liver disease, heart failure, neurodegenerative disease, and cardiac hypertrophy.
    Type: Application
    Filed: February 7, 2022
    Publication date: May 30, 2024
    Applicant: Rappta Therapeutics Oy
    Inventors: George L. Trainor, Maria Obdulia Rabal Gracia, Laura Fourmois, Olga Gherbovet, Frederic Cachoux
  • MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME
    Publication number: 20240174603
    Abstract: The present disclosure relates in part to chemical modulators of protein phosphatase 2A (PP2A), comprising formula (I). The compounds of the present disclosure are useful in treating, preventing, and/or ameliorating cancer, diabetes, autoimmune disease, solid organ transplant rejection, graft vs host disease, chronic obstructive pulmonary disease (COPD), non-alcoholic fatty liver disease, abdominal aortic aneurysm, chronic liver disease, heart failure, neurodegenerative disease, and cardiac hypertrophy.
    Type: Application
    Filed: February 7, 2022
    Publication date: May 30, 2024
    Applicant: Rappta Therapeutics Oy
    Inventors: George L. Trainor, Maria Obdulia Rabal Gracia, Laura Fourmois, Olga Gherbovet, Frederic Cachoux
  • Tricyclic Modulators of PP2A
    Publication number: 20230020161
    Abstract: Chemical modulators of PP2A, comprising tricyclic sulfonimidamides are disclosed. The compounds are useful in preventing or treating cancer, diabetes, autoimmune disease, solid organ transplant rejection, graft vs host disease, chronic obstructive pulmonary disease (COPD), non-alcoholic fatty liver disease, abdominal aortic aneurysm, chronic liver disease, heart failure, neurodegenerative disease and cardiac hypertrophy.
    Type: Application
    Filed: February 26, 2021
    Publication date: January 19, 2023
    Applicant: Rappta Therapeutics Oy
    Inventor: George L TRAINOR